Volume 4 Supplement 2

Current perspectives on the treatment of rheumatic diseases with infliximab

Reviews

Edited by Peter E Lipsky and Ravinder N Maini

Supported by an educational grant from Centocor, Inc.

The determination and measurement of functional disability in rheumatoid arthritis

Although functional outcome is frequently discussed and written about, it is often not clear what functional outcome is and how it can be measured. This paper introduces the concept of latent and observed meas...

Authors: Frederick Wolfe

Citation: Arthritis Research & Therapy 2002 4(Suppl 2):S11

Content type: Supplement Published on: 8 April 2002
- View Full Text
- View PDF
Current and future management approaches for rheumatoid arthritis

With the introduction of new disease-modifying antirheumatic drugs (DMARDs) and other therapeutic agents, the management of rheumatoid arthritis (RA) has shifted toward earlier, more aggressive therapy. The ul...

Authors: Ferdinand C Breedveld

Citation: Arthritis Research & Therapy 2002 4(Suppl 2):S16

Content type: Supplement Published on: 27 March 2002
- View Full Text
- View PDF
How does infliximab work in rheumatoid arthritis?

Since the initial characterization of tumor necrosis factor alpha (TNFα), it has become clear that TNFα has diverse biologic activity. The realization that TNFα plays a role in rheumatoid arthritis (RA) has le...

Authors: Ravinder N Maini and Marc Feldmann

Citation: Arthritis Research & Therapy 2002 4(Suppl 2):S22

Content type: Supplement Published on: 27 March 2002
- View Full Text
- View PDF
Structural damage in rheumatoid arthritis as visualized through radiographs

Several agents show an effect on reducing radiographic progression in rheumatoid arthritis. It is tempting to retrospectively compare the effects of these agents on radiographic progression across clinical tri...

Authors: Désirée van der Heijde

Citation: Arthritis Research & Therapy 2002 4(Suppl 2):S29

Content type: Supplement Published on: 27 March 2002
- View Full Text
- View PDF
Autoantibodies in rheumatoid arthritis and their clinical significance

Autoantibodies are proven useful diagnostic tools for a variety of rheumatic and non-rheumatic autoimmune disorders. However, a highly specific marker autoantibody for rheumatoid arthritis (RA) has not yet bee...

Authors: Günter Steiner and Josef Smolen

Citation: Arthritis Research & Therapy 2002 4(Suppl 2):S1

Content type: Supplement Published on: 26 April 2002
- View Full Text
- View PDF
Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases

Tumor necrosis factor alpha (TNF-α) is an inflammatory cytokine that has been implicated in a variety of rheumatic and inflammatory diseases. New understanding of the importance of TNF-α in the pathophysiology...

Authors: Joachim R Kalden

Citation: Arthritis Research & Therapy 2002 4(Suppl 2):S34

Content type: Supplement Published on: 24 May 2002
- View Full Text
- View PDF
Magnetic resonance imaging: opportunities for rheumatoid arthritis disease assessment and monitoring long-term treatment outcomes

Early diagnosis of rheumatoid arthritis (RA) combined with early initiation of an appropriate treatment regimen is acknowledged as an important factor in improving clinical outcomes in patients with RA. Early ...

Authors: Paul Emery

Citation: Arthritis Research & Therapy 2002 4(Suppl 2):S6

Content type: Supplement Published on: 18 April 2002
- View Full Text
- View PDF

Current perspectives on the treatment of rheumatic diseases with infliximab

Reviews

The determination and measurement of functional disability in rheumatoid arthritis

Current and future management approaches for rheumatoid arthritis

How does infliximab work in rheumatoid arthritis?

Structural damage in rheumatoid arthritis as visualized through radiographs

Autoantibodies in rheumatoid arthritis and their clinical significance

Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases

Magnetic resonance imaging: opportunities for rheumatoid arthritis disease assessment and monitoring long-term treatment outcomes

Follow

Annual Journal Metrics

Arthritis Research & Therapy

Contact us